Catalyst Brief

← Calendar

Readoutin 14d

Janssen Research & Development, LLC — Ibrutinib

Phase 3 primary completion: A Long-term Extension Study of PCI-32765 (Ibrutinib).

Date
Dec 2026
Type
Readout
Indication
Chronic Lymphocytic Leukemia

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Janssen Research & Development, LLC

  1. Feb2027
  2. Dec2026